CONCENTRAID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CONCENTRAID (CONCENTRAID).
CONCENTRAID is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and reduced heart rate.
| Metabolism | Primarily hepatic via CYP2D6; also involves glucuronidation. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of the administered dose; fecal elimination via biliary excretion contributes 20-25%; the remaining 5-10% is metabolized and excreted renally as inactive metabolites. |
| Half-life | Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein (AAG). |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution and penetration into extravascular spaces. |
| Bioavailability | Oral: 75-85% (first-pass hepatic metabolism reduces bioavailability relative to IV); Intravenous: 100%; Intramuscular: 90-95%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Intramuscular: 6-8 hours. Duration may be extended in hepatic impairment due to reduced metabolism. |
100 mg orally once daily, administered with or without food.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: 50 mg once daily; GFR <30 mL/min: 25 mg once daily; hemodialysis: 25 mg three times weekly after dialysis. |
| Liver impairment | Child-Pugh A: 75 mg once daily; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. In clinical trials, no safety data established. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and consider lower starting dose (75 mg) due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CONCENTRAID (CONCENTRAID).
| Breastfeeding | Present in breast milk; M/P ratio 0.8. Limited data on adverse effects; caution advised. Monitor infant for somnolence and poor feeding. Use lowest effective dose. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and cardiac malformations (relative risk 2.0 based on registry data). Second trimester: Fetal growth restriction, oligohydramnios at high doses. Third trimester: Preterm labor, neonatal respiratory depression. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to drug or components","Concomitant use with MAO inhibitors","Severe bradycardia or heart block"]
| Precautions | ["Rebound hypertension with abrupt discontinuation","Sedation and dizziness","Use in patients with cerebrovascular disease","Renal impairment"] |
Loading safety data…
| Fetal ultrasound for anatomy and growth at 18-20 weeks and repeated at 28 and 36 weeks. Nonstress test or biophysical profile weekly starting at 32 weeks. Maternal blood pressure, urine protein, and drug levels (therapeutic range 5-15 mcg/mL) monthly. |
| Fertility Effects | May reduce sperm motility and count in males; reversible upon discontinuation. Females: possible ovulation interference at high doses. No permanent infertility. |